giovedì, 30 marzo 2023

Notizie AIOM – anno XVII n. 742

22 Ottobre 2019

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019

October 18, 2019 - EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting. The Committee recommended granting a conditional marketing authorisation for Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live), the first ...
Leggi tutto

22 Ottobre 2019

Daratumumab Triplet Nears EU Approval for Frontline Transplant-Ineligible Myeloma

October 18, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed approval of daratumumab for use in combination with lenalidomide and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma ...
Leggi tutto

22 Ottobre 2019

EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC

October 18, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable ...
Leggi tutto

21 Ottobre 2019

FDA Grants Trastuzumab Deruxtecan Priority Review for HER2+ Breast Cancer

October 17, 2019 - The FDA has granted a priority review designation to a biologics license application (BLA) for trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer. The BLA is supported by data from a phase I trial2 ...
Leggi tutto

21 Ottobre 2019

European countries increase commitment to responsible antibiotic use in animals

October 15, 2019 - A report published by EMA shows that European countries continue to reduce the use of antibiotics in animals. The overall sales of veterinary antibiotics across Europe dropped by more than 32% between 2011 and 2017. In particular, two of the critically ...
Leggi tutto

21 Ottobre 2019

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard ...
Leggi tutto

21 Ottobre 2019

Exercise Intolerance, Mortality, and Organ System Impairment in Adult Survivors of Childhood Cancer

Exercise intolerance, associated with heart failure and death in general populations, is not well studied in survivors of childhood cancer. We examined prevalence of exercise intolerance in survivors exposed or not to cardiotoxic therapy, and associations among organ system ...
Leggi tutto

21 Ottobre 2019

14 ottobre 2019 – Attivazione web e pubblicazione schede di monitoraggio – Registro Apixaban (FANV) (Bristol-Myers Squibb/Pfizer)

21 Ottobre 2019

15 ottobre 2019 – Registro PT Web Apixaban (FANV) (Bristol-Myers Squibb/Pfizer) – Nuova Posologia

21 Ottobre 2019

15 ottobre 2019 – Registri AIFA: informazioni sui dati dei trattamenti con i nuovi farmaci per la cura dell’epatite C